Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

L.E.L. Hendriks*, J. Remon, J. Menis, B. Besse

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)2868-2875
Number of pages8
JournalTranslational Lung Cancer Research
Volume10
Issue number6
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • Non-small cell lung cancer (NSCLC)
  • brain metastases
  • immune checkpoint inhibitors
  • OPEN-LABEL
  • NSCLC
  • NIVOLUMAB
  • ATEZOLIZUMAB
  • BEVACIZUMAB
  • IPILIMUMAB
  • SURVIVAL
  • SYSTEM
  • PD-1

Cite this